BAX: A dedicated X-Rays galaxy clusters Database

We present BAX, Base de Donn\'ees amas de galaxies X (http://webast.ast.obs-mip.fr/bax), a project aiming at building a comprehensive database dedicated to X-rays clusters of galaxies allowing detailed information retrieval. BAX provides the user with {\it basic data} published in the literature on X-rays clusters of galaxies as well as with information concerning the physical properties in the X-rays domain or at other wavelengths. BAX allows individual studies on selected clusters as well as building up homogenous samples, from known X-rays clusters for which selection criteria are chosen through web interfaces. We expect BAX to become a useful tool for astronomy community in order to optimize the cluster science return using data from both ground based facilities like MEGACAM (CFHT), VIRMOS (VLT) and space missions like XMM, Chandra and Planck.Comment: 4 pages, 1 figure. Talk given at COSPAR conference in October 2002. To be published in the COSPAR proceedings (minor change

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial

BACKGROUND: The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination treatment is better than the sequential administration of the same drugs in patients with advanced colorectal cancer. METHODS: In this open-label, randomised, phase 3 trial, we randomly assigned patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and WHO performance status 0-2 to receive either first-line treatment with bolus (400 mg/m(2)) and infusional (2400 mg/m(2)) fluorouracil plus leucovorin (400 mg/m(2)) (simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m(2)) (FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m(2)) (FOLFIRI) or first-line FOLFOX6 and second-line FOLFIRI. Chemotherapy was administered every 2 weeks. Randomisation was done centrally using minimisation (minimisation factors were WHO performance status, previous adjuvant chemotherapy, number of disease sites, and centre). The primary endpoint was progression-free survival after two lines of treatment. Analyses were by intention-to-treat. This trial is registered at ClinicalTrials.gov, NCT00126256. FINDINGS: 205 patients were randomly assigned to the sequential group and 205 to the combination group. 161 (79%) patients in the sequential group and 161 (79%) in the combination group died during the study. Median progression-free survival after two lines was 10·5 months (95% CI 9·6-11·5) in the sequential group and 10·3 months (9·0-11·9) in the combination group (hazard ratio 0·95, 95% CI 0·77-1·16; p=0·61). All six deaths caused by toxic effects of treatment occurred in the combination group. During first-line chemotherapy, significantly fewer severe (grade 3-4) haematological adverse events (12 events in 203 patients in sequential group vs 83 events in 203 patients in combination group; p<0·0001) and non-haematological adverse events (26 events vs 186 events; p<0·0001) occurred in the sequential group than in the combination group. INTERPRETATION: Upfront combination chemotherapy is more toxic and is not more effective than the sequential use of the same cytotoxic drugs in patients with advanced, non-resectable colorectal cancer. FUNDING: Sanofi-Aventis France

Layered alkali rhodium oxides A<SUB>x</SUB>RhO<SUB>2</SUB>: topotactic solvation, exchange, and redox reactions

The intercalation/deintercalation properties of the layered oxides LiRhO<SUB>2</SUB>, NaRhO<SUB>2</SUB>, and KRhO<SUB>2</SUB> have been investigated with respect to redox and exchange processes. The chemical reactivity was found to be strongly dependent upon the alkali cation. Only KRhO<SUB>2</SUB> is able to form hydrated phases and to undergo quantitative K<SUP>+</SUP>/H<SUP>+</SUP> exchange, resulting in the formation of the new layered hydrogen bronze HRhO<SUB>2</SUB>. HRhO<SUB>2</SUB> has a limited phase range up to H<SUB>1.1</SUB>RhO<SUB>2</SUB> and exhibits no Br&#246;nsted acid character. LiRhO<SUB>2</SUB> and NaRhO<SUB>2</SUB> both show a limited cycling range in aprotic Li<SUP>+</SUP> or Na<SUP>+</SUP> electrolytes beyond which irreversible lattice disorder is observed. The origin of the significant differences in topotactic reactivity between layered dichalcogenide and oxide systems is discussed